Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post …
YL Wu, M Fukuoka, TSK Mok, N Saijo, S Thongprasert… - Lung cancer, 2013 - Elsevier
Abstract Background In IPASS (NCT00322452), progression-free survival (PFS, primary
endpoint) was significantly longer with first-line gefitinib versus carboplatin/paclitaxel in …
endpoint) was significantly longer with first-line gefitinib versus carboplatin/paclitaxel in …
[PDF][PDF] Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?
EN Suspitsin, EV Levchenko… - Onkologie-Zeitschrift …, 2011 - academia.edu
Evgeny N. Suspitsina, b Evgeny V. Levchenkoa Fedor V. Moiseyenkoa Alexandr O.
Ivantsova Samira A. Radzhabovaa Dmitry E. Matskoa Vladimir M. Moiseyenkoc Evgeny N …
Ivantsova Samira A. Radzhabovaa Dmitry E. Matskoa Vladimir M. Moiseyenkoc Evgeny N …
Dosis-Wirkungsbeziehungen von Gefitinib in einem humanen Lungentumormodell
EJD Weigl - 2020 - opus.bibliothek.uni-wuerzburg.de
Als die häufigste tödliche Tumorerkrankung weltweit ist das Lungenkarzinom mit einer sehr
schlechten Prognose verbunden. Eine Behandlungsoption für Lungenadenokarzinome, die …
schlechten Prognose verbunden. Eine Behandlungsoption für Lungenadenokarzinome, die …
Target therapy of gefitinib in advanced adenocarcinoma of the lung
H Zheng, W Jingping, M Qiyi, LIU Zan… - Zhongguo Fei Ai …, 2007 - search.proquest.com
吉非替尼是选择性表皮生长因子受体酪氨酸激酶抑制剂, 用于治疗非小细胞肺癌, 特别是腺癌.
本研究的目的是探讨吉非替尼在晚期肺腺癌中的疗效, 副反应及影响因素. 方法 收集 26 …
本研究的目的是探讨吉非替尼在晚期肺腺癌中的疗效, 副反应及影响因素. 方法 收集 26 …
[引用][C] Erlotinib in patient with non-small cell lung cancer: Significant symptomatic improvement within a few days but without change in chest X-ray
D Garfield, G Kashef - Lung Cancer, 2006 - lungcancerjournal.info
As regards the Letter to the Editor, entitled ''Gefitinib in patients with non-small cell lung
cancer: Symptomatic improvement within a few days''[1], we report the case of a 62 year-old …
cancer: Symptomatic improvement within a few days''[1], we report the case of a 62 year-old …